Evolus Earnings Call Highlights Profitable Growth Path

Evolus, Inc. ((EOLS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Evolus, Inc. struck an upbeat tone on its latest earnings call, pointing to steady revenue growth, resilient margins and a return to positive adjusted EBITDA as proof its strategy is working. Management acknowledged competitive and macro headwinds, but emphasized a building product pipeline and expanding customer base as key supports for the multi‑year growth story.

Revenue Growth and Brand Performance

Evolus reported Q1 global net revenue of $73.1 million, up 7% year over year, driven mainly by its flagship neurotoxin Jeuveau. Jeuveau generated $66.4 million with positive unit growth and stable pricing, while Evolisse added $6.7 million, and the company maintained a 14% U.S. share with expectations for high single‑digit Jeuveau growth this year.

Profitability Momentum

The company delivered its second straight quarter of positive adjusted EBITDA, posting $0.6 million versus a $5.5 million loss a year ago. Management framed the roughly $6.1 million improvement as evidence of operating discipline and reiterated a path to full‑year adjusted EBITDA profitability in 2026.

Healthy Margins

Gross profitability remained a key highlight, with reported Q1 gross margin at 67% and adjusted gross margin at 68%, excluding intangible amortization. Evolus reaffirmed its full‑year adjusted gross margin outlook of 65.5% to 67%, underscoring pricing resilience and cost control despite a competitive aesthetic market.

Commercial Reach and Engagement

Commercial metrics signaled broadening adoption as total purchasing accounts increased by nearly 500 in Q1, bringing lifetime purchasing customers above 18,000. U.S. account penetration now exceeds 60% with reorder rates around 71%, suggesting durable usage patterns across both Jeuveau and Evolisse.

Digital Ecosystem and Loyalty Growth

The Evolus Rewards ecosystem continued to scale, with membership approaching 1.5 million, up 27% year on year, and more than 255,000 redemptions in the quarter. Management highlighted efforts to embed AI into a unified data platform to sharpen field productivity and deliver more targeted customer engagement.

Pipeline and International Expansion

On the innovation front, Evolus pointed to Sculp, a mid‑face HA filler expected to secure FDA approval in Q4 2026, as a future growth driver and Evolisse complement. The company also flagged the mid‑May European launch of Esteem as a key step in international expansion, broadening its addressable market and supporting future U.S. launches.

Liquidity and Capital Flexibility

The balance sheet remains a focus, with quarter‑end cash and equivalents of $49.8 million and access to an additional $120 million through a term facility and revolver. Management stressed the mid‑2030 term loan maturity and modest roughly $3 million cash usage over the past two quarters as evidence of financial flexibility.

Operating Expenses and GAAP OpEx

GAAP operating expenses came in at $55.7 million for Q1, roughly flat sequentially compared with $55.1 million in Q4 as the company maintained investment levels. On a non‑GAAP basis, operating expenses improved to $49.1 million from $53.0 million, even as SG&A still carried about $4.8 million of non‑cash stock‑based compensation.

Cash Position Slight Decline

Evolus’ cash position eased modestly, falling from $53.8 million at the end of Q4 to $49.8 million at the end of Q1, a decline of about 7.4%. Management noted that existing cash, combined with available credit facilities, provides sufficient optionality to fund growth initiatives and navigate market volatility.

Seasonal and Timing Headwinds

Executives cautioned that Q1 results were distorted by one‑time revenue deferral dynamics that boosted comparisons for 2025 and created a headwind for 2026 figures. They expect U.S. Jeuveau net revenue in Q2 to more than offset the Q1 decline, smoothing the year’s trajectory and reinforcing confidence in demand.

Tariff Risk in South Korea

A new 15% tariff on certain pharmaceutical products in South Korea, including Jeuveau, is set to take effect in late 2026, introducing regulatory uncertainty in a key international market. Evolus is assessing mitigation levers and short‑term inventory strategies, but stressed that the potential impact will need close monitoring over time.

Evolisse Contribution and Market Headwinds

While Evolisse delivered $6.7 million in Q1 revenue, management acknowledged that the product remains a small contributor within a filler market that is flat to slightly down. Without Sculp, the portfolio lacks mid‑face coverage, and entrenched competitors are limiting near‑term share capture, tempering expectations for rapid filler‑side gains.

Competitive Environment Remains Active

The aesthetic neurotoxin arena remains crowded, with management calling out new entrants such as Galderma’s liquid toxin and aggressive sampling tactics. Evolus expects ongoing competition could pressure market share and will require continued commercial investment to defend and expand Jeuveau’s position.

Guidance and Long‑Term Outlook

Management reaffirmed 2026 guidance for total net revenue of $327 million to $337 million, implying 10% to 13% growth and adjusted gross margins of 65.5% to 67%. The company also maintained its outlook for non‑GAAP operating expenses of $210 million to $216 million, low‑ to mid‑single‑digit adjusted EBITDA margins, and high single‑digit global Jeuveau growth, supported by the Q1 print and liquidity.

Evolus’ latest call painted a picture of a company gaining operating leverage while investing for a broader aesthetic platform and international reach. For investors, the story hinges on management’s ability to navigate tariffs, competition and a soft filler market while delivering on reiterated guidance and converting its expanding pipeline into sustained, profitable growth.